Coronavirus impact: 30 March - a hint of resilience
The week has started with yet more dividend postponements and cancellations but also some fabulous results from one of the most resilient companies on the stock market.
Bioventix: reliability shines throughBioventix (LON:BVXP), the developer of high-affinity monoclonal antibodies for applications in clinical diagnostics, has announced excellent interim results for the six months ending 31 December 2019. Revenue rose 21% to £5.3m and pre-tax profit was up 31% to £4.3m. The operating cash inflow was £4m with period end cash £5.5m - cashflows are crucial companies attempt to battle a the period of lockdown. But Bioventix isn't facing as many challenges as other companies during the coronavirus lockdown. Healthcare products and services are priority products, with diagnostics among the most crucial. Management therefore expects its customers will continue to…